Zacks Investment Research upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a report issued on Wednesday, Zacks.com reports. They currently have $9.25 price objective on the stock.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Several other research firms have also recently commented on KPTI. Robert W. Baird restated an outperform rating and set a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a research note on Saturday, June 22nd. ValuEngine raised shares of Vistra Energy from a hold rating to a buy rating in a research note on Wednesday, July 3rd. HC Wainwright reaffirmed a buy rating and issued a $48.00 price objective (down previously from $52.00) on shares of CELYAD SA/ADR in a research note on Friday, July 5th. Finally, Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the company a hold rating in a research note on Monday, July 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $17.41.
Karyopharm Therapeutics stock opened at $8.03 on Wednesday. The firm’s fifty day moving average is $6.37. The company has a debt-to-equity ratio of 0.98, a quick ratio of 6.19 and a current ratio of 6.19. Karyopharm Therapeutics has a 12 month low of $3.92 and a 12 month high of $21.71.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.75 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -3.79 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in KPTI. PNC Financial Services Group Inc. lifted its stake in shares of Karyopharm Therapeutics by 660.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after purchasing an additional 3,300 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Karyopharm Therapeutics by 169,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after purchasing an additional 10,158 shares during the last quarter. Legal & General Group Plc lifted its position in Karyopharm Therapeutics by 31.3% during the 4th quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after acquiring an additional 2,411 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its position in Karyopharm Therapeutics by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $152,000 after acquiring an additional 12,711 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its position in Karyopharm Therapeutics by 24.4% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the company’s stock worth $234,000 after acquiring an additional 4,905 shares during the last quarter. 84.20% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Recommended Story: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.